Potent Inhibitors of the MAP Kinase p38

Authors

James R. Henry, Johnson & Johnson
Kenneth C. Rupert, Merck
John H. Dodd, Bristol-Myers SquibbFollow
Ignatius J. Turchi, Johnson & Johnson
Scott A. Wadsworth, Envigo PLCFollow
Druie E. Cavender, Newberry CollegeFollow
Peter H. Schafer, Bristol-Myers SquibbFollow
John Siekierka, Montclair State UniversityFollow

Document Type

Article

Publication Date

12-1-1998

Abstract

The MAP kinase p38 plays a key role in the biosynthesis of the inflammatory cytokines TNF-α and IL-1. We have developed a novel series of potent p38 inhibitors that could lead to new methods of treatment for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

DOI

10.1016/S0960-894X(98)00589-7

Montclair State University Digital Commons Citation

Henry, James R.; Rupert, Kenneth C.; Dodd, John H.; Turchi, Ignatius J.; Wadsworth, Scott A.; Cavender, Druie E.; Schafer, Peter H.; and Siekierka, John, "Potent Inhibitors of the MAP Kinase p38" (1998). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 359.
https://digitalcommons.montclair.edu/chem-biochem-facpubs/359